<?xml version="1.0" encoding="utf-8"?>
<Label drug="Tracleer" setid="749e42fb-2fe0-45dd-9268-b43bb3f4081c">
<Text><Section name="BOXED WARNING SECTION" id="34066-1">
WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY 

 Because of the risks of hepatotoxicity and birth defects, Tracleer is available only through a restricted program called the Tracleer REMS Program. The Tracleer REMS Program is a component of the Tracleer Risk Evaluation and Mitigation Strategy (REMS). Under the Tracleer REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions (5.3) ]. 

 WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY 

 See full prescribing information for complete boxed warning. 

 T racleer is available only through a restricted distribution program called the Tracleer REMS Program because of these risks ( 5.3 ): 

 Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with Tracleer ( 5.1 ). 

 Measure liver aminotransferases prior to initiation of treatment and then monthly ( 2.1 , 5.1 ). 

 Discontinue Tracleer if aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin ≥2 × ULN ( 2.4 , 5.1 ). 

 Based on animal data, Tracleer is likely to cause major birth defects if used during pregnancy ( 4.1 , 5.2 , 8.1 ). 

 Must exclude pregnancy before and during treatment ( 2.1 , 4.1 , 8.1 ). 

 To prevent pregnancy, females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping Tracleer ( 4.1 , 5.2 , 8.1 ). 

 Hepatotoxicity 

 In clinical studies, Tracleer caused at least 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferase levels must be measured prior to initiation of treatment and then monthly [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ] . In the postmarketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (&gt; 12 months) therapy with Tracleer in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of Tracleer in these cases could not be excluded. 

 In at least one case, the initial presentation (after &gt; 20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of Tracleer. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping Tracleer with a rise of aminotransferases accompanied by signs or symptoms of liver dysfunction [see Dosage and Administration (2.4) ] . 

 Elevations in aminotransferases require close attention [see Dosage and Administration (2.4) ] . Tracleer should generally be avoided in patients with elevated aminotransferases (&gt; 3 × ULN) at baseline because monitoring for hepatotoxicity may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥ 2 × ULN, treatment with Tracleer should be stopped. There is no experience with the reintroduction of Tracleer in these circumstances. 

 Embryo-Fetal Toxicity 

 Tracleer is likely to cause major birth defects if used by pregnant females based on animal data [see Warnings and Precautions (5.2) , Use in Specific Populations (8.1) ] . Therefore, pregnancy must be excluded before the start of treatment with Tracleer. Throughout treatment and for one month after stopping Tracleer, females of reproductive potential must use two reliable methods of contraception unless the patient has an intrauterine device (IUD) or tubal sterilization, in which case no other contraception is needed. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving Tracleer [see Drug Interactions (7.2) ] . Obtain monthly pregnancy tests.</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2. DOSAGE AND ADMINISTRATION 

 Patients older than 12 years of age: initiate at 62.5 mg orally twice daily; for patients weighing greater than 40 kg, increase to 125 mg orally twice daily after 4 weeks ( 2.1 ). 
 Patients 12 years of age and younger: dosage is is based on weight, see Table 1 ( 2.1 ). 
 Reduce the dose and closely monitor patients developing aminotransferase elevations more than 3 × Upper Limit of Normal (ULN) ( 2.2 ). 

 2.1 Required Monitoring 

 Healthcare professionals who prescribe Tracleer must enroll in the Tracleer REMS Program and must comply with the required monitoring to minimize the risks associated with Tracleer [see Warnings and Precautions (5.3) ]. 

 Obtain a pregnancy test in females of reproductive potential prior to Tracleer treatment, monthly during treatment and one month after stopping Tracleer. Initiate treatment with Tracleer in females of reproductive potential only after a negative pregnancy test [see Boxed Warning 
 , 
 Contraindications (4.1) , Warnings and Precautions (5.3) 
 , 
 Use in Specific Populations (8.1 , 8.3) ] . 
 Measure liver aminotransferase levels prior to initiation of treatment and then monthly [see Warnings and Precautions (5.1) ] . 

 2.2 Recommended Dosage 

 Administer Tracleer orally following the dosing recommendations in Table 1. Doses above 125 mg twice daily did not appear to confer additional benefit sufficient to offset the increased risk of hepatotoxicity. 

 Table 1: Dosing Recommendations 

 Initial 4 weeks 

 Maintenance (after 4 weeks) 

 Patients &gt;12 years of age and &gt;40 kg 

 62.5 mg twice daily 
 125 mg twice daily 

 Patients &gt;12 years of age and &lt;40 kg 

 62.5 mg twice daily 
 62.5 mg twice daily 

 Patients ≤12 years of age 

   ≥4-8 kg 

 16 mg twice daily 
 16 mg twice daily 

   &gt;8-16 kg 

 32 mg twice daily 
 32 mg twice daily 

   &gt;16-24 kg 

 48 mg twice daily 
 48 mg twice daily 

   &gt;24-40 kg 

 64 mg twice daily 
 64 mg twice daily 

 2.3 Administration 

 Tracleer film-coated tablets and tablets for oral suspension (dispersible tablets) should be administered orally twice daily. 
 Disperse tablets for oral suspension, or dispersable tablet half, in a minimal amount of water immediately before administration. 
 Store divided dispersible tablet pieces at 20ºC – 25ºC (68ºF – 77ºF) in the opened blister for up to 7 days. 

 2.4 Dosage Adjustments for Aminotransferase Elevations 

 If aminotransferase levels increase, adjust monitoring and treatment plan according to Table 2. 

 Discontinue Tracleer if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or bilirubin ≥ 2 × Upper Limit of Normal (ULN). There is no experience with the reintroduction of Tracleer in these circumstances. 

 Table 2: Dosage Adjustment and Monitoring in Patients Developing Aminotransferase Elevations &gt; 3 × ULN 

 ALT/AST levels 
 Treatment and monitoring recommendations 

 &gt; 3 and ≤ 5 × ULN 
 Confirm by another aminotransferase test; if confirmed, - in adults and pediatric patients &gt;12 years and &gt;40 kg , reduce the daily dose to 62.5 mg twice daily or interrupt treatment, and monitor aminotransferase levels at least every 2 weeks. If the aminotransferase levels return to pretreatment values, treatment may continue or be reintroduced at 62.5 mg twice daily, with reassessment of aminotransferase levels within 3 days. - in all other pediatric patients , interrupt treatment with no prior dose reduction. If the aminotransferase levels return to pretreatment values, reintroduce at the dose used prior to treatment interruption, with reassessment of aminotransferase levels within 3 days. 

 &gt; 5 and ≤ 8 × ULN 
 Confirm by another aminotransferase test; if confirmed, stop treatment and monitor aminotransferase levels at least every 2 weeks. Once the aminotransferase levels return to pretreatment values, - in adults and pediatric patients &gt;12 years and &gt;40 kg , consider reintroduction of treatment at 62.5 mg twice daily, with reassessment of aminotransferase levels within 3 days. - in all other pediatric patients , consider reintroduction at the dose used prior to treatment interruption, with reassessment of aminotransferase levels within 3 days. 

 &gt; 8 × ULN 
 Stop treatment permanently. There is no experience with reintroduction of Tracleer in these circumstances. 

 2.5 Use with Ritonavir 

 Co-administration of Tracleer in Patients on Ritonavir 

 In patients who have been receiving ritonavir for at least 10 days, start Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability [see Cytochrome P450 Drug Interactions (7.1) ] . 

 Co-administration of Ritonavir in Patients on Tracleer 

 Discontinue use of Tracleer at least 36 hours prior to initiation of ritonavir. After at least 10 days following the initiation of ritonavir, resume Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability [see Cytochrome P450 Drug Interactions (7.1) ] . 

 2.6 Use in Patients with Pre-existing Hepatic Impairment 

 Avoid initiation of Tracleer in patients with aminotransferases &gt;3 × ULN. No dose adjustment is required in patients with mildly impaired liver function [see Warnings and Precautions (5.3) , Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ].</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4. CONTRAINDICATIONS 

 Pregnancy ( 4.1 ) 
 Use with Cyclosporine A ( 4.2 ) 
 Use with Glyburide ( 4.3 ) 
 Hypersensitivity ( 4.4 ) 

 4.1 Pregnancy 

 Use of Tracleer is contraindicated in females who are or may become pregnant. To prevent pregnancy, females of reproductive potential must use two reliable forms of contraception during treatment and for one month after stopping Tracleer [see Boxed Warning , Warnings and Precautions (5.2) , Drug Interactions (7.2) , Use in Specific Populations (8.1) ] . 

 4.2 Use with Cyclosporine A 

 Co-administration of cyclosporine A and bosentan resulted in markedly increased plasma concentrations of bosentan. Therefore, concomitant use of Tracleer and cyclosporine A is contraindicated [see Cytochrome P450 Drug Interactions (7.1) ]. 

 4.3 Use with Glyburide 

 An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore co-administration of glyburide and Tracleer is contraindicated [see Cytochrome P450 Drug Interactions (7.1) ]. 

 4.4 Hypersensitivity 

 Tracleer is contraindicated in patients who are hypersensitive to bosentan or any component of the product. Observed reactions include Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), anaphylaxis, rash, and angioedema [see Adverse Reactions (6.2) , Description (11) ] .</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 Fluid retention: May require intervention ( 5.4 ). 
 Pulmonary veno-occlusive disease ( PVOD ) : If signs of pulmonary edema occur, consider the diagnosis of associated PVOD and consider discontinuing Tracleer ( 5.5 ). 
 Decreased sperm counts ( 5.6 ). 
 Decreases in hemoglobin and hematocrit: Monitor hemoglobin levels after 1 and 3 months of treatment, then every 3 months thereafter ( 5.7 ). 

 5.1 Hepatotoxicity 

 ALT or AST &gt; 3 × ULN were observed in 11% of Tracleer-treated patients (n = 658) compared to 2% of placebo-treated patients (n = 280). Three-fold increases were seen in 12% of 95 pulmonary arterial hypertension (PAH) patients on 125 mg twice daily and 14% of 70 PAH patients on 250 mg twice daily. Eight-fold increases were seen in 2% of PAH patients on 125 mg twice daily and 7% of PAH patients on 250 mg twice daily. Bilirubin increases to ≥ 3 × ULN were associated with aminotransferase increases in 2 of 658 (0.3%) of patients treated with Tracleer. In a pooled analysis of four pediatric studies conducted in PAH (n =100), elevations in liver aminotransferases ≥ 3 × ULN were observed in 2% of patients. The combination of hepatocellular injury (increases in aminotransferases of &gt; 3 × ULN) and increases in total bilirubin (≥ 2 × ULN) is a marker for potential serious hepatotoxicity. 
 Elevations of AST or ALT associated with Tracleer are dose-dependent, occur both early and late in treatment, usually progress slowly, are typically asymptomatic, and usually have been reversible after treatment interruption or cessation. Aminotransferase elevations also may reverse spontaneously while continuing treatment with Tracleer. 
 Liver aminotransferase levels must be measured prior to initiation of treatment and then monthly and therapy adjusted accordingly [see Dosage and Administration (2.1 , 2.4) ] . Discontinue Tracleer if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin ≥ 2 × ULN. 
 Avoid initiation of Tracleer in patients with elevated aminotransferases (&gt; 3 × ULN) prior to drug initiation because monitoring hepatotoxicity in these patients may be more difficult [see Boxed Warning , Dosage and Administration (2.6) , Use in Specific Populations (8.6) ] . 
 In WHO Functional Class II patients, consider whether the benefits of Tracleer are sufficient to offset the risk of hepatotoxicity, which may preclude future use as their disease progresses. 

 5.2 Embryo-fetal Toxicity 

 Based on data from animal reproduction studies, Tracleer may cause fetal harm when administered to a pregnant female and is contraindicated in females who are pregnant. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test prior to Tracleer treatment, monthly during treatment and for one month after stopping treatment. Advise females of reproductive potential to use two reliable forms of contraception during treatment with Tracleer and for at least one month after the last dose [see Dosage and Administration (2) , Use in Specific Populations (8.1 , 8.3) ] . 
 Tracleer is only available for females through a restricted program under REMS [see Warnings and Precautions (5.3) ]. 

 5.3 Prescribing and Distribution Program for Tracleer 

 Because of the risks of hepatotoxicity and birth defects, Tracleer is available only through a restricted program called the Tracleer REMS Program. As a component of the Tracleer REMS, prescribers, patients, and pharmacies must enroll in the program [see Boxed Warning , Warnings and Precautions (5.1 , 5.2) , Contraindications (4.1) ] . 
 Required components of the Tracleer REMS are: 

 Healthcare professionals who prescribe Tracleer must review the prescriber educational materials, enroll in the Tracleer REMS Program and comply with its requirements. 
 Healthcare professionals must (1) review serum aminotransferases (ALT/AST) and bilirubin, and agree to order and monitor these tests monthly; and (2) for females of reproductive potential, confirm that the patient is not pregnant, and agree to order and monitor pregnancy tests monthly. 
 To receive Tracleer, all patients must understand the risks and benefits, complete a patient enrollment form. 
 Pharmacies that dispense Tracleer must enroll in the program and agree to comply with the Tracleer REMS Program requirements. 

 Further information about Tracleer and the Tracleer REMS Program is available at www.Tracleerrems.com or 1-866-228-3546. 

 5.4 Fluid Retention 

 Peripheral edema is a known clinical consequence of PAH and worsening PAH and is also a known effect of Tracleer and other endothelin receptor antagonists. In PAH clinical trials with Tracleer, combined adverse events of fluid retention or edema were reported in 1.7% (placebo-corrected) of patients. 
 In addition, there have been numerous postmarketing reports of fluid retention in patients with pulmonary hypertension occurring within weeks after starting Tracleer. Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. 
 If clinically significant fluid retention develops, with or without associated weight gain, further evaluation should be undertaken to determine the cause, such as Tracleer or underlying heart failure, and the possible need for treatment or discontinuation of Tracleer [see Adverse Reactions (6.1) , Clinical Studies (14.2) ] . 

 5.5 Pulmonary Veno-Occlusive Disease 

 If signs of pulmonary edema occur, consider the possibility of associated pulmonary veno-occlusive disease and consider whether Tracleer should be discontinued. 

 5.6 Decreased Sperm Counts 

 Decreased sperm counts have been observed in patients receiving Tracleer. Preclinical data also suggest that Tracleer, similar to other endothelin receptor antagonists, may have an adverse effect on spermatogenesis [see Adverse Reactions (6.1) , Nonclinical Toxicology (13.1) ]. 

 5.7 Decreases in Hemoglobin and Hematocrit 

 Treatment with Tracleer can cause a dose-related decrease in hemoglobin and hematocrit. There have been postmarketing reports of decreases in hemoglobin concentration and hematocrit that have resulted in anemia requiring transfusion. It is recommended that hemoglobin concentrations be checked after 1 and 3 months, and every 3 months thereafter. If a marked decrease in hemoglobin concentration occurs, further evaluation should be undertaken to determine the cause and need for specific treatment [see Adverse Reactions (6.1) ] .</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7. DRUG INTERACTIONS 

 Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug ( 4.2 , 4.3 , 7.1 ) 
 Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness ( 7.2 ). 

 7.1 Cytochrome P450 Drug Interactions 

 Bosentan is metabolized by CYP2C9 and CYP3A. Inhibition of these enzymes may increase the plasma concentration of bosentan [see Pharmacokinetics (12.3) ] . Concomitant administration of both a CYP2C9 inhibitor (such as fluconazole or amiodarone) and a strong CYP3A inhibitor (e.g., ketoconazole, itraconazole) or a moderate CYP3A inhibitor (e.g., amprenavir, erythromycin, fluconazole, diltiazem) with Tracleer will likely lead to large increases in plasma concentrations of bosentan. Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with Tracleer is not recommended. 
 Bosentan is an inducer of CYP3A and CYP2C9. Consequently plasma concentrations of drugs metabolized by these two isozymes will be decreased when Tracleer is co-administered. Bosentan had no relevant inhibitory effect on any CYP isozyme in vitro (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A). Consequently, Tracleer is not expected to increase the plasma concentrations of drugs metabolized by these enzymes. 

 Figure 1. CYP3A induction-mediated effect of bosentan on other drugs 

 Figure 2. Effect of other drugs on bosentan 

 Figure 1 

 Figure 2 

 7.2 Hormonal Contraceptives 

 Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Tracleer is co-administered. Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking Tracleer [see Use in Specific Populations (8.3) ] . 
 An interaction study demonstrated that co-administration of bosentan and a combination oral hormonal contraceptive produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively. However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.</Section>
</Text><Sentences>
<Sentence id="323" LabelDrug="Tracleer" section="34066-1">
<SentenceText>Hormonal contraceptives , including oral , injectable , transdermal , and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving Tracleer see Drug Interactions ( 7.2 ) .</SentenceText>
<Mention id="M1" type="Trigger" span="101 18" str="should not be used"/>
<Mention id="M2" type="Precipitant" span="0 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M1" precipitant="M2"/>
</Sentence>
<Sentence id="324" LabelDrug="Tracleer" section="34068-7">
<SentenceText>After at least 10 days following the initiation of ritonavir , resume Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability see Cytochrome P450 Drug Interactions ( 7.1 ) .</SentenceText>
</Sentence>
<Sentence id="325" LabelDrug="Tracleer" section="34068-7">
<SentenceText>Co-administration of Ritonavir in Patients on Tracleer .</SentenceText>
</Sentence>
<Sentence id="326" LabelDrug="Tracleer" section="34068-7">
<SentenceText>Co-administration of Tracleer in Patients on Ritonavir .</SentenceText>
</Sentence>
<Sentence id="327" LabelDrug="Tracleer" section="34068-7">
<SentenceText>Discontinue use of Tracleer at least 36 hours prior to initiation of ritonavir .</SentenceText>
<Mention id="M3" type="Trigger" span="0 15" str="Discontinue use"/>
<Mention id="M4" type="Precipitant" span="69 9" str="ritonavir" code="N0000007423"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M3" precipitant="M4"/>
</Sentence>
<Sentence id="328" LabelDrug="Tracleer" section="34068-7">
<SentenceText>In patients who have been receiving ritonavir for at least 10 days , start Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability see Cytochrome P450 Drug Interactions ( 7.1 ) .</SentenceText>
</Sentence>
<Sentence id="329" LabelDrug="Tracleer" section="34070-3">
<SentenceText>An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan .</SentenceText>
<Mention id="M5" type="Trigger" span="3 14" str="increased risk"/>
<Mention id="M6" type="Precipitant" span="80 9" str="glyburide" code="N0000006295"/>
<Mention id="M7" type="SpecificInteraction" span="21 23" str="liver enzyme elevations" code="707724006: Elevated liver enzymes level (finding)"/>
<Interaction id="I3" type="Pharmacodynamic interaction" trigger="M5" precipitant="M6" effect="M7"/>
</Sentence>
<Sentence id="330" LabelDrug="Tracleer" section="34070-3">
<SentenceText>Co-administration of cyclosporine A and bosentan resulted in markedly increased plasma concentrations of bosentan .</SentenceText>
<Mention id="M8" type="Trigger" span="70 31" str="increased plasma concentrations"/>
<Mention id="M9" type="Precipitant" span="21 14" str="cyclosporine A" code="N0000007346"/>
<Interaction id="I4" type="Pharmacokinetic interaction" trigger="M8" precipitant="M9" effect="C54355"/>
</Sentence>
<Sentence id="331" LabelDrug="Tracleer" section="34070-3">
<SentenceText>Therefore , concomitant use of Tracleer and cyclosporine A is contraindicated see Cytochrome P450 Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M10" type="Trigger" span="62 15" str="contraindicated"/>
<Mention id="M11" type="Precipitant" span="44 14" str="cyclosporine A" code="N0000007346"/>
<Interaction id="I5" type="Unspecified interaction" trigger="M10" precipitant="M11"/>
</Sentence>
<Sentence id="332" LabelDrug="Tracleer" section="34070-3">
<SentenceText>Therefore co-administration of glyburide and Tracleer is contraindicated see Cytochrome P450 Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M12" type="Trigger" span="57 15" str="contraindicated"/>
<Mention id="M13" type="Precipitant" span="31 9" str="glyburide" code="N0000006295"/>
<Interaction id="I6" type="Unspecified interaction" trigger="M12" precipitant="M13"/>
</Sentence>
<Sentence id="333" LabelDrug="Tracleer" section="34073-7">
<SentenceText>An interaction study demonstrated that co-administration of bosentan and a combination oral hormonal contraceptive produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .</SentenceText>
<Mention id="M14" type="Trigger" span="132 9;181 6" str="decreases | levels"/>
<Mention id="M15" type="Precipitant" span="75 39" str="combination oral hormonal contraceptive" code="NO MAP"/>
<Interaction id="I7" type="Pharmacokinetic interaction" trigger="M14" precipitant="M15" effect="C54358"/>
</Sentence>
<Sentence id="334" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Bosentan had no relevant inhibitory effect on any CYP isozyme in vitro (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A).</SentenceText>
</Sentence>
<Sentence id="335" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Bosentan is an inducer of CYP3A and CYP2C9.</SentenceText>
</Sentence>
<Sentence id="336" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Bosentan is metabolized by CYP2C9 and CYP3A.</SentenceText>
</Sentence>
<Sentence id="337" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with Tracleer is not recommended.</SentenceText>
<Mention id="M16" type="Trigger" span="120 15" str="not recommended"/>
<Mention id="M17" type="Precipitant" span="44 16;68 34" str="CYP2C9 inhibitor | strong or moderate CYP3A inhibitor" code="n0000185504"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M16" precipitant="M17"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M36" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M19" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M21" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M23" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M25" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M27" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M29" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M31" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M33" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M35" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M37" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I9" type="Pharmacokinetic interaction" trigger="M36" precipitant="M19" effect="C54355"/>
<Interaction id="I10" type="Pharmacokinetic interaction" trigger="M36" precipitant="M21" effect="C54355"/>
<Interaction id="I11" type="Pharmacokinetic interaction" trigger="M36" precipitant="M23" effect="C54355"/>
<Interaction id="I12" type="Pharmacokinetic interaction" trigger="M36" precipitant="M25" effect="C54355"/>
<Interaction id="I13" type="Pharmacokinetic interaction" trigger="M36" precipitant="M27" effect="C54355"/>
<Interaction id="I14" type="Pharmacokinetic interaction" trigger="M36" precipitant="M29" effect="C54355"/>
<Interaction id="I15" type="Pharmacokinetic interaction" trigger="M36" precipitant="M31" effect="C54355"/>
<Interaction id="I16" type="Pharmacokinetic interaction" trigger="M36" precipitant="M33" effect="C54355"/>
<Interaction id="I17" type="Pharmacokinetic interaction" trigger="M36" precipitant="M35" effect="C54355"/>
<Interaction id="I18" type="Pharmacokinetic interaction" trigger="M36" precipitant="M37" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M56" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M39" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M41" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M43" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M45" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M47" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M49" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M51" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M53" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M55" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M57" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I19" type="Pharmacokinetic interaction" trigger="M56" precipitant="M39" effect="C54355"/>
<Interaction id="I20" type="Pharmacokinetic interaction" trigger="M56" precipitant="M41" effect="C54355"/>
<Interaction id="I21" type="Pharmacokinetic interaction" trigger="M56" precipitant="M43" effect="C54355"/>
<Interaction id="I22" type="Pharmacokinetic interaction" trigger="M56" precipitant="M45" effect="C54355"/>
<Interaction id="I23" type="Pharmacokinetic interaction" trigger="M56" precipitant="M47" effect="C54355"/>
<Interaction id="I24" type="Pharmacokinetic interaction" trigger="M56" precipitant="M49" effect="C54355"/>
<Interaction id="I25" type="Pharmacokinetic interaction" trigger="M56" precipitant="M51" effect="C54355"/>
<Interaction id="I26" type="Pharmacokinetic interaction" trigger="M56" precipitant="M53" effect="C54355"/>
<Interaction id="I27" type="Pharmacokinetic interaction" trigger="M56" precipitant="M55" effect="C54355"/>
<Interaction id="I28" type="Pharmacokinetic interaction" trigger="M56" precipitant="M57" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M76" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M59" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M61" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M63" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M65" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M67" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M69" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M71" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M73" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M75" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M77" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I29" type="Pharmacokinetic interaction" trigger="M76" precipitant="M59" effect="C54355"/>
<Interaction id="I30" type="Pharmacokinetic interaction" trigger="M76" precipitant="M61" effect="C54355"/>
<Interaction id="I31" type="Pharmacokinetic interaction" trigger="M76" precipitant="M63" effect="C54355"/>
<Interaction id="I32" type="Pharmacokinetic interaction" trigger="M76" precipitant="M65" effect="C54355"/>
<Interaction id="I33" type="Pharmacokinetic interaction" trigger="M76" precipitant="M67" effect="C54355"/>
<Interaction id="I34" type="Pharmacokinetic interaction" trigger="M76" precipitant="M69" effect="C54355"/>
<Interaction id="I35" type="Pharmacokinetic interaction" trigger="M76" precipitant="M71" effect="C54355"/>
<Interaction id="I36" type="Pharmacokinetic interaction" trigger="M76" precipitant="M73" effect="C54355"/>
<Interaction id="I37" type="Pharmacokinetic interaction" trigger="M76" precipitant="M75" effect="C54355"/>
<Interaction id="I38" type="Pharmacokinetic interaction" trigger="M76" precipitant="M77" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M96" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M79" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M81" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M83" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M85" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M87" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M89" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M91" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M93" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M95" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M97" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I39" type="Pharmacokinetic interaction" trigger="M96" precipitant="M79" effect="C54355"/>
<Interaction id="I40" type="Pharmacokinetic interaction" trigger="M96" precipitant="M81" effect="C54355"/>
<Interaction id="I41" type="Pharmacokinetic interaction" trigger="M96" precipitant="M83" effect="C54355"/>
<Interaction id="I42" type="Pharmacokinetic interaction" trigger="M96" precipitant="M85" effect="C54355"/>
<Interaction id="I43" type="Pharmacokinetic interaction" trigger="M96" precipitant="M87" effect="C54355"/>
<Interaction id="I44" type="Pharmacokinetic interaction" trigger="M96" precipitant="M89" effect="C54355"/>
<Interaction id="I45" type="Pharmacokinetic interaction" trigger="M96" precipitant="M91" effect="C54355"/>
<Interaction id="I46" type="Pharmacokinetic interaction" trigger="M96" precipitant="M93" effect="C54355"/>
<Interaction id="I47" type="Pharmacokinetic interaction" trigger="M96" precipitant="M95" effect="C54355"/>
<Interaction id="I48" type="Pharmacokinetic interaction" trigger="M96" precipitant="M97" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M116" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M99" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M101" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M103" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M105" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M107" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M109" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M111" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M113" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M115" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M117" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I49" type="Pharmacokinetic interaction" trigger="M116" precipitant="M99" effect="C54355"/>
<Interaction id="I50" type="Pharmacokinetic interaction" trigger="M116" precipitant="M101" effect="C54355"/>
<Interaction id="I51" type="Pharmacokinetic interaction" trigger="M116" precipitant="M103" effect="C54355"/>
<Interaction id="I52" type="Pharmacokinetic interaction" trigger="M116" precipitant="M105" effect="C54355"/>
<Interaction id="I53" type="Pharmacokinetic interaction" trigger="M116" precipitant="M107" effect="C54355"/>
<Interaction id="I54" type="Pharmacokinetic interaction" trigger="M116" precipitant="M109" effect="C54355"/>
<Interaction id="I55" type="Pharmacokinetic interaction" trigger="M116" precipitant="M111" effect="C54355"/>
<Interaction id="I56" type="Pharmacokinetic interaction" trigger="M116" precipitant="M113" effect="C54355"/>
<Interaction id="I57" type="Pharmacokinetic interaction" trigger="M116" precipitant="M115" effect="C54355"/>
<Interaction id="I58" type="Pharmacokinetic interaction" trigger="M116" precipitant="M117" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M136" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M119" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M121" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M123" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M125" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M127" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M129" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M131" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M133" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M135" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M137" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I59" type="Pharmacokinetic interaction" trigger="M136" precipitant="M119" effect="C54355"/>
<Interaction id="I60" type="Pharmacokinetic interaction" trigger="M136" precipitant="M121" effect="C54355"/>
<Interaction id="I61" type="Pharmacokinetic interaction" trigger="M136" precipitant="M123" effect="C54355"/>
<Interaction id="I62" type="Pharmacokinetic interaction" trigger="M136" precipitant="M125" effect="C54355"/>
<Interaction id="I63" type="Pharmacokinetic interaction" trigger="M136" precipitant="M127" effect="C54355"/>
<Interaction id="I64" type="Pharmacokinetic interaction" trigger="M136" precipitant="M129" effect="C54355"/>
<Interaction id="I65" type="Pharmacokinetic interaction" trigger="M136" precipitant="M131" effect="C54355"/>
<Interaction id="I66" type="Pharmacokinetic interaction" trigger="M136" precipitant="M133" effect="C54355"/>
<Interaction id="I67" type="Pharmacokinetic interaction" trigger="M136" precipitant="M135" effect="C54355"/>
<Interaction id="I68" type="Pharmacokinetic interaction" trigger="M136" precipitant="M137" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M156" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M139" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M141" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M143" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M145" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M147" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M149" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M151" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M153" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M155" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M157" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I69" type="Pharmacokinetic interaction" trigger="M156" precipitant="M139" effect="C54355"/>
<Interaction id="I70" type="Pharmacokinetic interaction" trigger="M156" precipitant="M141" effect="C54355"/>
<Interaction id="I71" type="Pharmacokinetic interaction" trigger="M156" precipitant="M143" effect="C54355"/>
<Interaction id="I72" type="Pharmacokinetic interaction" trigger="M156" precipitant="M145" effect="C54355"/>
<Interaction id="I73" type="Pharmacokinetic interaction" trigger="M156" precipitant="M147" effect="C54355"/>
<Interaction id="I74" type="Pharmacokinetic interaction" trigger="M156" precipitant="M149" effect="C54355"/>
<Interaction id="I75" type="Pharmacokinetic interaction" trigger="M156" precipitant="M151" effect="C54355"/>
<Interaction id="I76" type="Pharmacokinetic interaction" trigger="M156" precipitant="M153" effect="C54355"/>
<Interaction id="I77" type="Pharmacokinetic interaction" trigger="M156" precipitant="M155" effect="C54355"/>
<Interaction id="I78" type="Pharmacokinetic interaction" trigger="M156" precipitant="M157" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M176" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M159" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M161" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M163" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M165" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M167" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M169" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M171" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M173" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M175" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M177" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I79" type="Pharmacokinetic interaction" trigger="M176" precipitant="M159" effect="C54355"/>
<Interaction id="I80" type="Pharmacokinetic interaction" trigger="M176" precipitant="M161" effect="C54355"/>
<Interaction id="I81" type="Pharmacokinetic interaction" trigger="M176" precipitant="M163" effect="C54355"/>
<Interaction id="I82" type="Pharmacokinetic interaction" trigger="M176" precipitant="M165" effect="C54355"/>
<Interaction id="I83" type="Pharmacokinetic interaction" trigger="M176" precipitant="M167" effect="C54355"/>
<Interaction id="I84" type="Pharmacokinetic interaction" trigger="M176" precipitant="M169" effect="C54355"/>
<Interaction id="I85" type="Pharmacokinetic interaction" trigger="M176" precipitant="M171" effect="C54355"/>
<Interaction id="I86" type="Pharmacokinetic interaction" trigger="M176" precipitant="M173" effect="C54355"/>
<Interaction id="I87" type="Pharmacokinetic interaction" trigger="M176" precipitant="M175" effect="C54355"/>
<Interaction id="I88" type="Pharmacokinetic interaction" trigger="M176" precipitant="M177" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M196" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M179" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M181" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M183" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M185" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M187" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M189" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M191" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M193" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M195" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M197" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I89" type="Pharmacokinetic interaction" trigger="M196" precipitant="M179" effect="C54355"/>
<Interaction id="I90" type="Pharmacokinetic interaction" trigger="M196" precipitant="M181" effect="C54355"/>
<Interaction id="I91" type="Pharmacokinetic interaction" trigger="M196" precipitant="M183" effect="C54355"/>
<Interaction id="I92" type="Pharmacokinetic interaction" trigger="M196" precipitant="M185" effect="C54355"/>
<Interaction id="I93" type="Pharmacokinetic interaction" trigger="M196" precipitant="M187" effect="C54355"/>
<Interaction id="I94" type="Pharmacokinetic interaction" trigger="M196" precipitant="M189" effect="C54355"/>
<Interaction id="I95" type="Pharmacokinetic interaction" trigger="M196" precipitant="M191" effect="C54355"/>
<Interaction id="I96" type="Pharmacokinetic interaction" trigger="M196" precipitant="M193" effect="C54355"/>
<Interaction id="I97" type="Pharmacokinetic interaction" trigger="M196" precipitant="M195" effect="C54355"/>
<Interaction id="I98" type="Pharmacokinetic interaction" trigger="M196" precipitant="M197" effect="C54355"/>
</Sentence>
<Sentence id="338" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .</SentenceText>
<Mention id="M216" type="Trigger" span="293 9;306 21" str="increases | plasma concentrations"/>
<Mention id="M199" type="Precipitant" span="79 10" str="amiodarone" code="N0000005761"/>
<Mention id="M201" type="Precipitant" span="199 10" str="amprenavir" code="N0000004336"/>
<Mention id="M203" type="Precipitant" span="37 16" str="CYP2C9 inhibitor" code="n0000185504"/>
<Mention id="M205" type="Precipitant" span="241 9" str="diltiazem" code="N0000006682"/>
<Mention id="M207" type="Precipitant" span="212 12" str="erythromycin" code="N0000007133"/>
<Mention id="M209" type="Precipitant" span="64 11" str="fluconazole" code="N0000006331"/>
<Mention id="M211" type="Precipitant" span="145 12" str="itraconazole" code="N0000006753"/>
<Mention id="M213" type="Precipitant" span="130 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M215" type="Precipitant" span="165 24" str="moderate CYP3A inhibitor" code="n0000182141"/>
<Mention id="M217" type="Precipitant" span="98 22" str="strong CYP3A inhibitor" code="n0000191001"/>
<Interaction id="I99" type="Pharmacokinetic interaction" trigger="M216" precipitant="M199" effect="C54355"/>
<Interaction id="I100" type="Pharmacokinetic interaction" trigger="M216" precipitant="M201" effect="C54355"/>
<Interaction id="I101" type="Pharmacokinetic interaction" trigger="M216" precipitant="M203" effect="C54355"/>
<Interaction id="I102" type="Pharmacokinetic interaction" trigger="M216" precipitant="M205" effect="C54355"/>
<Interaction id="I103" type="Pharmacokinetic interaction" trigger="M216" precipitant="M207" effect="C54355"/>
<Interaction id="I104" type="Pharmacokinetic interaction" trigger="M216" precipitant="M209" effect="C54355"/>
<Interaction id="I105" type="Pharmacokinetic interaction" trigger="M216" precipitant="M211" effect="C54355"/>
<Interaction id="I106" type="Pharmacokinetic interaction" trigger="M216" precipitant="M213" effect="C54355"/>
<Interaction id="I107" type="Pharmacokinetic interaction" trigger="M216" precipitant="M215" effect="C54355"/>
<Interaction id="I108" type="Pharmacokinetic interaction" trigger="M216" precipitant="M217" effect="C54355"/>
</Sentence>
<Sentence id="339" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Consequently plasma concentrations of drugs metabolized by these two isozymes will be decreased when Tracleer is co-administered.</SentenceText>
</Sentence>
<Sentence id="340" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Consequently, Tracleer is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.</SentenceText>
</Sentence>
<Sentence id="341" LabelDrug="Tracleer" section="34073-7">
<SentenceText>CYP3A induction-mediated effect of bosentan on other drugs .</SentenceText>
</Sentence>
<Sentence id="342" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).</SentenceText>
<Mention id="M224" type="Trigger" span="93 17" str="increase exposure"/>
<Mention id="M221" type="Precipitant" span="51 17;83 5" str="drugs metabolized | CYP3A" code="NO MAP"/>
<Mention id="M225" type="Precipitant" span="51 27" str="drugs metabolized by CYP2C9" code="NO MAP"/>
<Mention id="M226" type="Trigger" span="208 9;102 8" str="decreases | exposure"/>
<Mention id="M227" type="Precipitant" span="170 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I109" type="Pharmacokinetic interaction" trigger="M224" precipitant="M221" effect="C54355"/>
<Interaction id="I110" type="Pharmacokinetic interaction" trigger="M224" precipitant="M221" effect="C54357"/>
<Interaction id="I111" type="Pharmacokinetic interaction" trigger="M224" precipitant="M225" effect="C54355"/>
<Interaction id="I112" type="Pharmacokinetic interaction" trigger="M224" precipitant="M225" effect="C54357"/>
<Interaction id="I113" type="Pharmacokinetic interaction" trigger="M226" precipitant="M227" effect="C54358"/>
</Sentence>
<Sentence id="342" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).</SentenceText>
<Mention id="M234" type="Trigger" span="93 17" str="increase exposure"/>
<Mention id="M231" type="Precipitant" span="51 17;83 5" str="drugs metabolized | CYP3A" code="NO MAP"/>
<Mention id="M235" type="Precipitant" span="51 27" str="drugs metabolized by CYP2C9" code="NO MAP"/>
<Mention id="M236" type="Trigger" span="208 9;102 8" str="decreases | exposure"/>
<Mention id="M237" type="Precipitant" span="170 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I114" type="Pharmacokinetic interaction" trigger="M234" precipitant="M231" effect="C54355"/>
<Interaction id="I115" type="Pharmacokinetic interaction" trigger="M234" precipitant="M231" effect="C54357"/>
<Interaction id="I116" type="Pharmacokinetic interaction" trigger="M234" precipitant="M235" effect="C54355"/>
<Interaction id="I117" type="Pharmacokinetic interaction" trigger="M234" precipitant="M235" effect="C54357"/>
<Interaction id="I118" type="Pharmacokinetic interaction" trigger="M236" precipitant="M237" effect="C54358"/>
</Sentence>
<Sentence id="342" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).</SentenceText>
<Mention id="M244" type="Trigger" span="93 17" str="increase exposure"/>
<Mention id="M241" type="Precipitant" span="51 17;83 5" str="drugs metabolized | CYP3A" code="NO MAP"/>
<Mention id="M245" type="Precipitant" span="51 27" str="drugs metabolized by CYP2C9" code="NO MAP"/>
<Mention id="M246" type="Trigger" span="208 9;102 8" str="decreases | exposure"/>
<Mention id="M247" type="Precipitant" span="170 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I119" type="Pharmacokinetic interaction" trigger="M244" precipitant="M241" effect="C54355"/>
<Interaction id="I120" type="Pharmacokinetic interaction" trigger="M244" precipitant="M241" effect="C54357"/>
<Interaction id="I121" type="Pharmacokinetic interaction" trigger="M244" precipitant="M245" effect="C54355"/>
<Interaction id="I122" type="Pharmacokinetic interaction" trigger="M244" precipitant="M245" effect="C54357"/>
<Interaction id="I123" type="Pharmacokinetic interaction" trigger="M246" precipitant="M247" effect="C54358"/>
</Sentence>
<Sentence id="342" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).</SentenceText>
<Mention id="M254" type="Trigger" span="93 17" str="increase exposure"/>
<Mention id="M251" type="Precipitant" span="51 17;83 5" str="drugs metabolized | CYP3A" code="NO MAP"/>
<Mention id="M255" type="Precipitant" span="51 27" str="drugs metabolized by CYP2C9" code="NO MAP"/>
<Mention id="M256" type="Trigger" span="208 9;102 8" str="decreases | exposure"/>
<Mention id="M257" type="Precipitant" span="170 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I124" type="Pharmacokinetic interaction" trigger="M254" precipitant="M251" effect="C54355"/>
<Interaction id="I125" type="Pharmacokinetic interaction" trigger="M254" precipitant="M251" effect="C54357"/>
<Interaction id="I126" type="Pharmacokinetic interaction" trigger="M254" precipitant="M255" effect="C54355"/>
<Interaction id="I127" type="Pharmacokinetic interaction" trigger="M254" precipitant="M255" effect="C54357"/>
<Interaction id="I128" type="Pharmacokinetic interaction" trigger="M256" precipitant="M257" effect="C54358"/>
</Sentence>
<Sentence id="342" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).</SentenceText>
<Mention id="M264" type="Trigger" span="93 17" str="increase exposure"/>
<Mention id="M261" type="Precipitant" span="51 17;83 5" str="drugs metabolized | CYP3A" code="NO MAP"/>
<Mention id="M265" type="Precipitant" span="51 27" str="drugs metabolized by CYP2C9" code="NO MAP"/>
<Mention id="M266" type="Trigger" span="208 9;102 8" str="decreases | exposure"/>
<Mention id="M267" type="Precipitant" span="170 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I129" type="Pharmacokinetic interaction" trigger="M264" precipitant="M261" effect="C54355"/>
<Interaction id="I130" type="Pharmacokinetic interaction" trigger="M264" precipitant="M261" effect="C54357"/>
<Interaction id="I131" type="Pharmacokinetic interaction" trigger="M264" precipitant="M265" effect="C54355"/>
<Interaction id="I132" type="Pharmacokinetic interaction" trigger="M264" precipitant="M265" effect="C54357"/>
<Interaction id="I133" type="Pharmacokinetic interaction" trigger="M266" precipitant="M267" effect="C54358"/>
</Sentence>
<Sentence id="343" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Effect of other drugs on bosentan Figure 1 Figure 2 Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Tracleer is co-administered.</SentenceText>
</Sentence>
<Sentence id="344" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking Tracleer [see Use in Specific Populations (8.3)].</SentenceText>
</Sentence>
<Sentence id="345" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Hormonal contraceptives , including oral , injectable , transdermal , and implantable forms , may not be reliable when Tracleer is co-administered .</SentenceText>
</Sentence>
<Sentence id="346" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Hormonal contraceptives : Tracleer use decreases contraceptive exposure and reduces effectiveness ( 7.2 ) .</SentenceText>
<Mention id="M268" type="Trigger" span="39 9;63 8" str="decreases | exposure"/>
<Mention id="M269" type="Precipitant" span="0 23" str="Hormonal contraceptives" code="NO MAP"/>
<Interaction id="I134" type="Pharmacokinetic interaction" trigger="M268" precipitant="M269" effect="C54358"/>
</Sentence>
<Sentence id="347" LabelDrug="Tracleer" section="34073-7">
<SentenceText>However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.</SentenceText>
</Sentence>
<Sentence id="348" LabelDrug="Tracleer" section="34073-7">
<SentenceText>Inhibition of these enzymes may increase the plasma concentration of bosentan [see Pharmacokinetics (12.3)].</SentenceText>
</Sentence>
<Sentence id="349" LabelDrug="Tracleer" section="43685-7">
<SentenceText>Peripheral edema is a known clinical consequence of PAH and worsening PAH and is also a known effect of Tracleer and other endothelin receptor antagonists .</SentenceText>
</Sentence>
<Sentence id="350" LabelDrug="Tracleer" section="43685-7">
<SentenceText>Preclinical data also suggest that Tracleer , similar to other endothelin receptor antagonists , may have an adverse effect on spermatogenesis see Adverse Reactions ( 6.1 ) , Nonclinical Toxicology ( 13.1 ) .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacokinetic interaction" precipitant="hormonal contraceptives" precipitantCode="NO MAP" effect="C54358"/>
<LabelInteraction type="Unspecified interaction" precipitant="hormonal contraceptives" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="ritonavir" precipitantCode="N0000007423"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="glyburide" precipitantCode="N0000006295" effect="707724006: Elevated liver enzymes level (finding)"/>
<LabelInteraction type="Unspecified interaction" precipitant="glyburide" precipitantCode="N0000006295"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine a" precipitantCode="N0000007346" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyclosporine a" precipitantCode="N0000007346"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="combination oral hormonal contraceptive" precipitantCode="NO MAP" effect="C54358"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyp2c9 inhibitor | strong or moderate cyp3a inhibitor" precipitantCode="n0000185504"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="amiodarone" precipitantCode="N0000005761" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="amprenavir" precipitantCode="N0000004336" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp2c9 inhibitor" precipitantCode="n0000185504" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="diltiazem" precipitantCode="N0000006682" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="erythromycin" precipitantCode="N0000007133" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="fluconazole" precipitantCode="N0000006331" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="itraconazole" precipitantCode="N0000006753" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ketoconazole" precipitantCode="N0000007319" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="moderate cyp3a inhibitor" precipitantCode="n0000182141" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="strong cyp3a inhibitor" precipitantCode="n0000191001" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="drugs metabolized | cyp3a" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="drugs metabolized | cyp3a" precipitantCode="NO MAP" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="drugs metabolized by cyp2c9" precipitantCode="NO MAP" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="drugs metabolized by cyp2c9" precipitantCode="NO MAP" effect="C54357"/>

</LabelInteractions></Label>